GFRα4 CAR T Cells in MTC Patients

Metastatic Medullary Thyroid Cancer Clinical Trial

Official title:
Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer

Status Recruiting

Clinical Trial Summary

This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Neuroendocrine
Metastatic Medullary Thyroid Cancer
Thyroid Neoplasms

Clinical Trial Details

NCT number	NCT04877613
Study type	Interventional
Source	University of Pennsylvania
Contact	Abramson Cancer Center Clinical Trials Service
Phone	855-216-0098
Email	PennCancerTrials@careboxhealth.com
Status	Recruiting
Phase	Phase 1
Start date	August 19, 2021
Completion date	June 1, 2039

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT01927887` - Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study	N/A
Completed	`NCT00654238` - Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer	Phase 2
Completed	`NCT02109250` - CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice	N/A